Trial reports first successful results for heart failure with preserved ejection fraction
Empagliflozin reduces the risk of a composite of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction (HFpEF) with or without diabetes. That's the finding ...
Aug 27, 2021
0
176